However, it is unlikely that any methodological differences would influence the observed associations, as a large validation study comparing registry reports of receptor status to those of a single expert laboratory found only small differences in risk estimates for ER+/PR+ and ER-/PR- breast cancer between the two sources [59]. Here, ESR1 is linked to breast cancer.